Leukemia research, 2013-09, Vol.37 (9), p.1077-1082
2013
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Sequence of novel agents in multiple myeloma: An instrumental variable analysis
- Ist Teil von
- Leukemia research, 2013-09, Vol.37 (9), p.1077-1082
- Ort / Verlag
- England: Elsevier Ltd
- Erscheinungsjahr
- 2013
- Quelle
- ScienceDirect
- Beschreibungen/Notizen
- Abstract Lenalidomide and bortezomib have not been compared prospectively and are currently used in sequence for patients with multiple myeloma; however, it is unknown whether a sequence of administration could result in improved outcomes. We retrospectively reviewed electronic records of patients with multiple myeloma who had used both agents in sequence at our institution: 97 patients had lenalidomide first and 111 had bortezomib first. On multivariable analysis, the sequence of therapy was not associated with outcome. These findings were confirmed with instrumental variable analyses. Finally, use of bortezomib first was associated with improved survival for patients with baseline renal insufficiency.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0145-2126eISSN: 1873-5835DOI: 10.1016/j.leukres.2013.06.005Titel-ID: cdi_proquest_miscellaneous_1500759031
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Boronic Acids - administration & dosage, Bortezomib, Drug Administration Schedule, Female, Follow-Up Studies, Hematology, Oncology and Palliative Medicine, Humans, Lenalidomide, Male, Middle Aged, Multiple myeloma, Multiple Myeloma - drug therapy, Multiple Myeloma - mortality, Neoplasm Recurrence, Local - drug therapy, Neoplasm Recurrence, Local - mortality, Outcome, Prognosis, Pyrazines - administration & dosage, Remission Induction, Retrospective Studies, Survival, Survival Rate, Thalidomide - administration & dosage, Thalidomide - analogs & derivatives